

Eugenii A. Rabiner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8910450/publications.pdf>

Version: 2024-02-01

173
papers

12,106
citations

20817

60
h-index

30087

103
g-index

177
all docs

177
docs citations

177
times ranked

11518
citing authors

#	ARTICLE	IF	CITATIONS
1	An 18-kDa Translocator Protein (TSPO) Polymorphism Explains Differences in Binding Affinity of the PET Radioligand PBR28. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1-5.	4.3	642
2	Brain Serotonin _{1A} Receptor Binding Measured by Positron Emission Tomography With [¹¹ C]WAY-100635. <i>Archives of General Psychiatry</i> , 2000, 57, 174.	12.3	597
3	Fibromyalgia patients show an abnormal dopamine response to pain. <i>European Journal of Neuroscience</i> , 2007, 25, 3576-3582.	2.6	362
4	Imaging dopamine receptors in humans with [¹¹ C]-(+)-PHNO: Dissection of D3 signal and anatomy. <i>NeuroImage</i> , 2011, 54, 264-277.	4.2	359
5	Mixed-Affinity Binding in Humans with 18-kDa Translocator Protein Ligands. <i>Journal of Nuclear Medicine</i> , 2011, 52, 24-32.	5.0	330
6	The Gut Hormones PYY ₃₋₃₆ and GLP-1 ₇₋₃₆ amide Reduce Food Intake and Modulate Brain Activity in Appetite Centers in Humans. <i>Cell Metabolism</i> , 2011, 14, 700-706.	16.2	288
7	Tremor in Parkinson's disease and serotonergic dysfunction. <i>Neurology</i> , 2003, 60, 601-605.	1.1	277
8	Connectivity-Based Functional Analysis of Dopamine Release in the Striatum Using Diffusion-Weighted MRI and Positron Emission Tomography. <i>Cerebral Cortex</i> , 2014, 24, 1165-1177.	2.9	276
9	Tracer Kinetic Modeling of the 5-HT _{1A} Receptor Ligand [carbonyl- ¹¹ C]WAY-100635 for PET. <i>NeuroImage</i> , 1998, 8, 426-440.	4.2	267
10	Positron emission tomography molecular imaging for drug development. <i>British Journal of Clinical Pharmacology</i> , 2012, 73, 175-186.	2.4	263
11	A Functional Genetic Variation of the Serotonin (5-HT) Transporter Affects 5-HT _{1A} Receptor Binding in Humans. <i>Journal of Neuroscience</i> , 2005, 25, 2586-2590.	3.6	253
12	Persistent reduction in brain serotonin _{1A} receptor binding in recovered depressed men measured by positron emission tomography with [¹¹ C]WAY-100635. <i>Molecular Psychiatry</i> , 2004, 9, 386-392.	7.9	231
13	Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 46-50.	4.3	231
14	Two Binding Sites for [³ H]PBR28 in Human Brain: Implications for TSPO PET Imaging of Neuroinflammation. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 1608-1618.	4.3	187
15	Serotonin 5-HT _{1A} receptor binding in people with panic disorder: positron emission tomography study. <i>British Journal of Psychiatry</i> , 2008, 193, 229-234.	2.8	166
16	Dopamine (D _{2/3}) receptor agonist positron emission tomography radiotracer [¹¹ C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. <i>Synapse</i> , 2006, 60, 485-495.	1.2	159
17	Pro-inflammatory activation of primary microglia and macrophages increases 18-kDa translocator protein expression in rodents but not humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 2679-2690.	4.3	153
18	Within-Subject Comparison of [¹¹ C]-(+)-PHNO and [¹¹ C]raclopride Sensitivity to Acute Amphetamine Challenge in Healthy Humans. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 127-136.	4.3	150

#	ARTICLE	IF	CITATIONS
19	Synaptic density marker SV2A is reduced in schizophrenia patients and unaffected by antipsychotics in rats. <i>Nature Communications</i> , 2020, 11, 246.	12.8	148
20	Imaging Dopamine D3 Receptors in the Human Brain with Positron Emission Tomography, [¹¹ C]PHNO, and a Selective D3 Receptor Antagonist. <i>Biological Psychiatry</i> , 2010, 68, 392-399.	1.3	140
21	Neuroinflammation in treated HIV-positive individuals. <i>Neurology</i> , 2016, 86, 1425-1432.	1.1	136
22	A Database of [¹¹ C]WAY-100635 Binding to 5-HT1A Receptors in Normal Male Volunteers: Normative Data and Relationship to Methodological, Demographic, Physiological, and Behavioral Variables. <i>NeuroImage</i> , 2002, 15, 620-632.	4.2	133
23	Positron emission tomography imaging of amphetamine-induced dopamine release in the human cortex: A comparative evaluation of the high affinity dopamine D _{2/3} radiotracers [¹¹ C]FLB 457 and [¹¹ C]fallypride. <i>Synapse</i> , 2009, 63, 447-461.	1.2	127
24	In vivo quantification of regional dopamine D ₃ receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. <i>Synapse</i> , 2009, 63, 782-793.	1.2	127
25	The Development, Past Achievements, and Future Directions of Brain PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 1426-1454.	4.3	119
26	Glucagon increases energy expenditure independently of brown adipose tissue activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2016, 18, 72-81.	4.4	118
27	Determination of [¹¹ C]PBR28 Binding Potential <i>in vivo</i> : A First Human TSPO Blocking Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 989-994.	4.3	117
28	Quantification of the Specific Translocator Protein Signal of ¹⁸ F-PBR111 in Healthy Humans: A Genetic Polymorphism Effect on In Vivo Binding. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1915-1923.	5.0	105
29	Endogenous Opioid Release in the Human Brain Reward System Induced by Acute Amphetamine Administration. <i>Biological Psychiatry</i> , 2012, 72, 371-377.	1.3	104
30	Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis. <i>Biological Psychiatry</i> , 2016, 80, 62-72.	1.3	103
31	Brain 5-HT1A receptor binding in chronic fatigue syndrome measured using positron emission tomography and [¹¹ C]WAY-100635. <i>Biological Psychiatry</i> , 2005, 57, 239-246.	1.3	100
32	Positron Emission Tomography Quantification of [¹¹ C]-Harmine Binding to Monoamine Oxidase-A in the Human Brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2006, 26, 330-344.	4.3	100
33	Loss of phosphodiesterase 10A expression is associated with progression and severity in Parkinson's disease. <i>Brain</i> , 2015, 138, 3003-3015.	7.6	100
34	Blunted Endogenous Opioid Release Following an Oral Amphetamine Challenge in Pathological Gamblers. <i>Neuropsychopharmacology</i> , 2016, 41, 1742-1750.	5.4	96
35	[¹¹ C]-WAY100635 PET demonstrates marked 5-HT1A receptor changes in sporadic ALS. <i>Brain</i> , 2005, 128, 896-905.	7.6	92
36	Altered PDE10A expression detectable early before symptomatic onset in Huntington's disease. <i>Brain</i> , 2015, 138, 3016-3029.	7.6	90

#	ARTICLE	IF	CITATIONS
37	Pharmacological differentiation of opioid receptor antagonists by molecular and functional imaging of target occupancy and food reward-related brain activation in humans. <i>Molecular Psychiatry</i> , 2011, 16, 826-835.	7.9	89
38	A Multi-Center Randomized Proof-of-Concept Clinical Trial Applying [18F]FDG-PET for Evaluation of Metabolic Therapy with Rosiglitazone XR in Mild to Moderate Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 22, 1241-1256.	2.6	86
39	Advances in CNS PET: the state-of-the-art for new imaging targets for pathophysiology and drug development. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 451-489.	6.4	86
40	Opioids and anxiety. <i>Journal of Psychopharmacology</i> , 2011, 25, 1415-1433.	4.0	85
41	Amphetamine induced endogenous opioid release in the human brain detected with [11C]carfentanil PET: replication in an independent cohort. <i>International Journal of Neuropsychopharmacology</i> , 2014, 17, 2069-2074.	2.1	85
42	Kisspeptin modulates sexual and emotional brain processing in humans. <i>Journal of Clinical Investigation</i> , 2017, 127, 709-719.	8.2	85
43	Kinetic Modeling of ¹¹ C-SB207145 Binding to 5-HT ₄ Receptors in the Human Brain In Vivo. <i>Journal of Nuclear Medicine</i> , 2009, 50, 900-908.	5.0	84
44	Serotonin transporter polymorphisms (SLC6A4 insertion/deletion and rs25531) do not affect the availability of 5-HTT to [11C] DASB binding in the living human brain. <i>NeuroImage</i> , 2010, 52, 50-54.	4.2	83
45	In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with ¹⁸ F-PBR111 PET. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1112-1118.	5.0	82
46	Pindolol Augmentation of Selective Serotonin Reuptake Inhibitors: PET Evidence That the Dose Used in Clinical Trials Is Too Low. <i>American Journal of Psychiatry</i> , 2001, 158, 2080-2082.	7.2	80
47	Central 5-HT ₄ receptor binding as biomarker of serotonergic tonus in humans: a [11C]SB207145 PET study. <i>Molecular Psychiatry</i> , 2014, 19, 427-432.	7.9	80
48	<i>TSPO</i> mutations in rats and a human polymorphism impair the rate of steroid synthesis. <i>Biochemical Journal</i> , 2017, 474, 3985-3999.	3.7	80
49	Comparison of four ¹¹ C-labeled PET ligands to quantify translocator protein 18 kDa (<i>TSPO</i>) in human brain: (R)-PK11195, PBR28, DPA-713, and ER176 based on recent publications that measured specific-to-non-displaceable ratios. <i>EJNMMI Research</i> , 2017, 7, 84.	2.5	80
50	Occupancy of Brain Dopamine D ₃ Receptors and Drug Craving: A Translational Approach. <i>Neuropsychopharmacology</i> , 2013, 38, 302-312.	5.4	76
51	Neuroinflammation and its relationship to changes in brain volume and white matter lesions in multiple sclerosis. <i>Brain</i> , 2017, 140, 2927-2938.	7.6	75
52	Affinity and selectivity of [¹¹ C]α(+)-PHNO for the D ₃ and D ₂ receptors in the rhesus monkey brain in vivo. <i>Synapse</i> , 2012, 66, 489-500.	1.2	74
53	Identifying improved <i>TSPO</i> PET imaging probes through biomathematics: The impact of multiple <i>TSPO</i> binding sites in vivo. <i>NeuroImage</i> , 2012, 60, 902-910.	4.2	73
54	Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson's disease: an in vivo ¹¹ C-BU99008 PET study. <i>Brain</i> , 2019, 142, 3116-3128.	7.6	73

#	ARTICLE	IF	CITATIONS
55	β-blocker Binding to Human 5-HT1A Receptors in vivo and in vitro Implications for Antidepressant Therapy. <i>Neuropsychopharmacology</i> , 2000, 23, 285-293.	5.4	70
56	Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. <i>Lancet Neurology</i> , The, 2019, 18, 748-759.	10.2	70
57	Evaluation of ¹¹ C-GSK189254 as a Novel Radioligand for the H3 Receptor in Humans Using PET. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1021-1029.	5.0	68
58	Positron emission tomography imaging of the 18-kDa translocator protein (TSPO) with [¹⁸ F]FEMPA in Alzheimer's disease patients and control subjects. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 438-446.	6.4	64
59	Drug action at the 5-HT1A receptor in vivo: autoreceptor and postsynaptic receptor occupancy examined with PET and [carbonyl- ¹¹ C]WAY-100635. <i>Nuclear Medicine and Biology</i> , 2000, 27, 509-513.	0.6	63
60	Orbitofrontal Connectivity with Resting-State Networks Is Associated with Midbrain Dopamine D3 Receptor Availability. <i>Cerebral Cortex</i> , 2012, 22, 2784-2793.	2.9	62
61	Evaluation of ¹¹ C-BU99008, a PET Ligand for the Imidazoline ₂ Binding Site in Human Brain. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1597-1602.	5.0	61
62	Prediction of Repeat-Dose Occupancy from Single-Dose Data: Characterisation of the Relationship between Plasma Pharmacokinetics and Brain Target Occupancy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2011, 31, 944-952.	4.3	59
63	Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. <i>Journal of Psychopharmacology</i> , 2013, 27, 424-434.	4.0	57
64	¹¹ C-PBR28 and ¹⁸ F-PBR111 Detect White Matter Inflammatory Heterogeneity in Multiple Sclerosis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1477-1482.	5.0	57
65	Decreased hippocampal translocator protein (18 kDa) expression in alcohol dependence: a [¹¹ C]PBR28 PET study. <i>Translational Psychiatry</i> , 2017, 7, e996-e996.	4.8	56
66	Radiosynthesis and Characterization of ¹¹ C-GSK215083 as a PET Radioligand for the 5-HT6 Receptor. <i>Journal of Nuclear Medicine</i> , 2012, 53, 295-303.	5.0	53
67	In Vivo Imaging of Cerebral Dopamine D3 Receptors in Alcoholism. <i>Neuropsychopharmacology</i> , 2014, 39, 1703-1712.	5.4	53
68	Does cannabis affect dopaminergic signaling in the human brain? A systematic review of evidence to date. <i>European Neuropsychopharmacology</i> , 2015, 25, 1201-1224.	0.7	53
69	Characterization of 3 PET Tracers for Quantification of Mitochondrial and Synaptic Function in Healthy Human Brain: ¹⁸ F-BCPP-EF, ¹¹ C-SA-4503, and ¹¹ C-UCB-J. <i>Journal of Nuclear Medicine</i> , 2020, 61, 96-103.	5.0	53
70	Translational PET imaging research. <i>Neurobiology of Disease</i> , 2014, 61, 32-38.	4.4	51
71	¹¹ C-DPA-713 has much greater specific binding to translocator protein 18 kDa (TSPO) in human brain than ¹¹ C-(R)-PK11195. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 393-403.	4.3	51
72	Thermal Imaging Is a Noninvasive Alternative to PET/CT for Measurement of Brown Adipose Tissue Activity in Humans. <i>Journal of Nuclear Medicine</i> , 2018, 59, 516-522.	5.0	51

#	ARTICLE	IF	CITATIONS
73	Phosphodiesterase 10A PET Radioligand Development Program: From Pig to Human. <i>Journal of Nuclear Medicine</i> , 2014, 55, 595-601.	5.0	50
74	Mitochondrial Complex 1, Sigma 1, and Synaptic Vesicle α 2A in Early Drug-Naive Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1416-1427.	3.9	48
75	Bipolar Disorder is associated with the rs6971 polymorphism in the gene encoding 18kDa Translocator Protein (TSPO). <i>Psychoneuroendocrinology</i> , 2013, 38, 2826-2829.	2.7	47
76	Dopamine D3 receptor ligands for drug addiction treatment. <i>Progress in Brain Research</i> , 2014, 211, 255-275.	1.4	47
77	Occupancy of Agonist Drugs at the 5-HT1A Receptor. <i>Neuropsychopharmacology</i> , 2004, 29, 847-859.	5.4	46
78	Translational characterization of [11 C]GSK931145, a PET ligand for the glycine transporter type 1. <i>Synapse</i> , 2011, 65, 1319-1332.	1.2	46
79	Translocator Protein as an Imaging Marker of Macrophage and Stromal Activation in Rheumatoid Arthritis Pannus. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1125-1132.	5.0	46
80	5-Hydroxytryptamine 1A Receptor Occupancy by Novel Full Antagonist 2-[4-[4-(7-Chloro-2,3-dihydro-1,4-benzodioxyn-5-yl)-1-piperazinyl]butyl]-1,2-benzisothiazol-3-(2H)-one-1,1-dioxide: A [11 C][O-methyl-3H]-N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide Trihydrochloride (WAY-100635) Positron Emission Tomography Study in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 301, 1144-1150.	2.5	44
81	Imaging Nicotine- and Amphetamine-Induced Dopamine Release in Rhesus Monkeys with [11 C]PHNO vs [11 C]raclopride PET. <i>Neuropsychopharmacology</i> , 2014, 39, 866-874.	5.4	43
82	Astrocyte reactivity with late-onset cognitive impairment assessed in vivo using 11 C-BU99008 PET and its relationship with amyloid load. <i>Molecular Psychiatry</i> , 2021, 26, 5848-5855.	7.9	43
83	Radiosynthesis and in vivo evaluation of [11 C]MP-10 as a positron emission tomography radioligand for phosphodiesterase 10A. <i>Nuclear Medicine and Biology</i> , 2011, 38, 875-884.	0.6	42
84	Radiation dose estimates for carbon-11-labelled PET tracers. <i>Nuclear Medicine and Biology</i> , 2012, 39, 305-314.	0.6	42
85	Positron emission tomography imaging of dopamine D2/3 receptors in the human cortex with [11 C]FLB 457: Reproducibility studies. <i>Synapse</i> , 2011, 65, 35-40.	1.2	41
86	In Vivo Binding of Antipsychotics to D3 and D2 Receptors: A PET Study in Baboons with [11 C]-(+)-PHNO. <i>Neuropsychopharmacology</i> , 2011, 36, 887-895.	5.4	41
87	Evaluation of EMD 128 130 occupancy of the 5-HT1A and the D2 receptor: a human PET study with [11 C]WAY-100635 and [11 C]raclopride. <i>Journal of Psychopharmacology</i> , 2002, 16, 195-199.	4.0	40
88	A Graphical Method to Compare the <i>in vivo</i> Binding Potential of PET Radioligands in the Absence of a Reference Region: Application to [11 C]PBR28 and [18 F]PBR111 for TSPO Imaging. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2014, 34, 1162-1168.	4.3	38
89	Imaging in Central Nervous System Drug Discovery. <i>Seminars in Nuclear Medicine</i> , 2017, 47, 89-98.	4.6	38
90	PDE10A and ADCY5 mutations linked to molecular and microstructural basal ganglia pathology. <i>Movement Disorders</i> , 2018, 33, 1961-1965.	3.9	38

#	ARTICLE	IF	CITATIONS
91	Loss of extra-striatal phosphodiesterase 10A expression in early premanifest Huntington's disease gene carriers. <i>Journal of the Neurological Sciences</i> , 2016, 368, 243-248.	0.6	37
92	Evaluation of dopamine D _{2/3} -specific binding in the cerebellum for the positron emission tomography radiotracer [¹¹ C]FLB 457: Implications for measuring cortical dopamine release. <i>Synapse</i> , 2011, 65, 991-997.	1.2	35
93	Presynaptic 5-HT1A is Related to 5-HTT Receptor Density in the Human Brain. <i>Neuropsychopharmacology</i> , 2011, 36, 2258-2265.	5.4	35
94	PET studies in drug development: Methodological considerations. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 311-315.	4.0	34
95	Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge. <i>Neuropsychopharmacology</i> , 2020, 45, 804-810.	5.4	34
96	Preferential 5-HT1A Autoreceptor Occupancy by Pindolol is Attenuated in Depressed Patients: Effect of Treatment or an Endophenotype of Depression?. <i>Neuropsychopharmacology</i> , 2004, 29, 1688-1698.	5.4	33
97	Mathematical modelling of [11C]-(+)-PHNO human competition studies. <i>NeuroImage</i> , 2013, 68, 119-132.	4.2	33
98	Phosphodiesterase 10A in Schizophrenia: A PET Study Using [¹¹ C]JMA107. <i>American Journal of Psychiatry</i> , 2016, 173, 714-721.	7.2	33
99	5-HT1A receptor binding in euthymic bipolar patients using positron emission tomography with [carbonyl-11C]WAY-100635. <i>Journal of Affective Disorders</i> , 2010, 123, 77-80.	4.1	32
100	Non-invasive imaging in experimental medicine for drug development. <i>Current Opinion in Pharmacology</i> , 2011, 11, 501-507.	3.5	32
101	Unexpectedly high affinity of a novel histamine H ₃ receptor antagonist, GSK239512, <i>in vivo</i> in human brain, determined using PET. <i>British Journal of Pharmacology</i> , 2014, 171, 1241-1249.	5.4	32
102	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. <i>Neurology</i> , 2016, 87, 2451-2456.	1.1	32
103	Nalmefene Reduces Reward Anticipation in Alcohol Dependence: An Experimental Functional Magnetic Resonance Imaging Study. <i>Biological Psychiatry</i> , 2017, 81, 941-948.	1.3	32
104	The application of positron emission tomography (PET) imaging in CNS drug development. <i>Brain Imaging and Behavior</i> , 2019, 13, 354-365.	2.1	32
105	Imaging of striatal dopamine release elicited with NMDA antagonists: is there anything there to be seen?. <i>Journal of Psychopharmacology</i> , 2007, 21, 253-258.	4.0	31
106	Loss of phosphodiesterase 4 in Parkinson disease. <i>Neurology</i> , 2017, 89, 586-593.	1.1	30
107	Reduced mu opioid receptor availability in schizophrenia revealed with [11C]-carfentanil positron emission tomographic imaging. <i>Nature Communications</i> , 2019, 10, 4493.	12.8	30
108	Characterization of <i>in vivo</i> pharmacological properties and sensitivity to endogenous serotonin of [¹¹ C] P943: A positron emission tomography study in <i>Papio anubis</i> . <i>Synapse</i> , 2011, 65, 1119-1127.	1.2	28

#	ARTICLE	IF	CITATIONS
109	A pharmacokinetic PET study of NK1 receptor occupancy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 226-235.	6.4	28
110	The impact of the rs6971 polymorphism in TSPO for quantification and study design. <i>Clinical and Translational Imaging</i> , 2015, 3, 417-422.	2.1	28
111	Imaging Cortical Dopamine D1 Receptors Using [¹¹ C]NNC112 and Ketanserin Blockade of the 5-HT _{2A} Receptors. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2010, 30, 985-993.	4.3	27
112	Dynamic, Adaptive Changes in MAO-A Binding after Alterations in Substrate Availability: An <i>in vivo</i> [¹¹ C]-Harmine Positron Emission Tomography Study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2012, 32, 443-446.	4.3	27
113	The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description. <i>Journal of Psychopharmacology</i> , 2015, 29, 943-960.	4.0	27
114	The relationship between synaptic density marker SV2A, glutamate and N-acetyl aspartate levels in healthy volunteers and schizophrenia: a multimodal PET and magnetic resonance spectroscopy brain imaging study. <i>Translational Psychiatry</i> , 2021, 11, 393.	4.8	27
115	Modulations of human resting brain connectivity by kisspeptin enhance sexual and emotional functions. <i>JCI Insight</i> , 2018, 3, .	5.0	26
116	Disease-related patterns of <i>in vivo</i> pathology in Corticobasal syndrome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 2413-2425.	6.4	26
117	Evaluation of Novel <i>N</i> -Methyl-2-phenylindol-3-ylglyoxylamides as a New Chemotype of 18 kDa Translocator Protein-Selective Ligand Suitable for the Development of Positron Emission Tomography Radioligands. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 366-373.	6.4	25
118	Cerebral serotonin transporter measurements with [¹¹ C]DASB: A review on acquisition and preprocessing across 21 PET centres. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2019, 39, 210-222.	4.3	25
119	Imaging the D3 receptor in humans <i>in vivo</i> using [¹¹ C](+)-PHNO positron emission tomography (PET). <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 289.	2.1	24
120	Human Kinetic Modeling of the 5HT ₆ PET Radioligand [¹¹ C]-GSK215083 and Its Utility for Determining Occupancy at Both 5HT ₆ and 5HT _{2A} Receptors by SB742457 as a Potential Therapeutic Mechanism of Action in Alzheimer Disease. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1901-1909.	5.0	24
121	Evidence for GABA _A receptor dysregulation in gambling disorder: correlation with impulsivity. <i>Addiction Biology</i> , 2017, 22, 1601-1609.	2.6	24
122	Kisspeptin enhances brain responses to olfactory and visual cues of attraction in men. <i>JCI Insight</i> , 2020, 5, .	5.0	24
123	<i>In vitro</i> assessment of the agonist properties of the novel 5-HT _{1A} receptor ligand, CUMI-101 (MMP), in rat brain tissue. <i>Nuclear Medicine and Biology</i> , 2011, 38, 273-277.	0.6	23
124	An evaluation of the brain distribution of [¹¹ C]GSK1034702, a muscarinic-1 (M1) positive allosteric modulator in the living human brain using positron emission tomography. <i>EJNMMI Research</i> , 2014, 4, 66.	2.5	23
125	Translocator positron-emission tomography and magnetic resonance spectroscopic imaging of brain glial cell activation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1469-1478.	3.0	23
126	Blunted endogenous opioid release following an oral dexamphetamine challenge in abstinent alcohol-dependent individuals. <i>Molecular Psychiatry</i> , 2020, 25, 1749-1758.	7.9	23

#	ARTICLE	IF	CITATIONS
127	Relationship Between Glycine Transporter 1 Inhibition as Measured with Positron Emission Tomography and Changes in Cognitive Performances in Nonhuman Primates. <i>Neuropsychopharmacology</i> , 2014, 39, 2742-2749.	5.4	22
128	Cortical 5-HT1A receptor binding in patients with homozygous D90A SOD1 vs sporadic ALS. <i>Neurology</i> , 2007, 68, 1233-1235.	1.1	21
129	Are prescribed benzodiazepines likely to affect the availability of the 18 kDa translocator protein (TSPO) in PET studies?. <i>Synapse</i> , 2013, 67, 909-912.	1.2	21
130	Novel PET Biomarkers to Disentangle Molecular Pathways across Age-Related Neurodegenerative Diseases. <i>Cells</i> , 2020, 9, 2581.	4.1	20
131	Awake Nonhuman Primate Brain PET Imaging with Minimal Head Restraint: Evaluation of GABA _A -Benzodiazepine Binding with ¹¹ C-Flumazenil in Awake and Anesthetized Animals. <i>Journal of Nuclear Medicine</i> , 2013, 54, 1962-1968.	5.0	19
132	Characterising the plasma-target occupancy relationship of the neurokinin antagonist GSK1144814 with PET. <i>Journal of Psychopharmacology</i> , 2014, 28, 244-253.	4.0	19
133	Relationship between astrocyte reactivity, using novel ¹¹ C-BU99008 PET, and glucose metabolism, grey matter volume and amyloid load in cognitively impaired individuals. <i>Molecular Psychiatry</i> , 2022, 27, 2019-2029.	7.9	19
134	Further evaluation of [¹¹ C]MP-10 as a radiotracer for phosphodiesterase 10A: PET imaging study in rhesus monkeys and brain tissue metabolite analysis. <i>Synapse</i> , 2015, 69, 86-95.	1.2	18
135	Evidence of Brain Inflammation in Patients with Human T-Lymphotropic Virus Type 1 Associated Myelopathy (HAM): A Pilot, Multimodal Imaging Study Using ¹¹ C-PBR28 PET, MR T1-Weighted, and Diffusion-Weighted Imaging. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1905-1912.	5.0	18
136	Accuracy and reliability of [¹¹ C]PBR28 specific binding estimated without the use of a reference region. <i>NeuroImage</i> , 2019, 188, 102-110.	4.2	18
137	DREADD Activation of Pedunculopontine Cholinergic Neurons Reverses Motor Deficits and Restores Striatal Dopamine Signaling in Parkinsonian Rats. <i>Neurotherapeutics</i> , 2020, 17, 1120-1141.	4.4	18
138	Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [¹¹ C]-PBR28 and Machine Learning Analysis. <i>Movement Disorders</i> , 2022, 37, 119-129.	3.9	18
139	Monoamine Transporter Occupancy of a Novel Triple Reuptake Inhibitor in Baboons and Humans Using Positron Emission Tomography. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2013, 346, 311-317.	2.5	16
140	Effect of chronic antipsychotic treatment on striatal phosphodiesterase 10A levels: a [¹¹ C]MP-10 PET rodent imaging study with ex vivo confirmation. <i>Translational Psychiatry</i> , 2014, 4, e376-e376.	4.8	16
141	Comparison of phosphodiesterase 10A and dopamine transporter levels as markers of disease burden in early Parkinson's disease. <i>Movement Disorders</i> , 2019, 34, 1505-1515.	3.9	15
142	Test-retest variability and reference region-based quantification of ¹⁸ F-BCPP-EF for imaging mitochondrial complex I in the human brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 771-779.	4.3	15
143	The Effects of Kisspeptin on Brain Response to Food Images and Psychometric Parameters of Appetite in Healthy Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 1837-1848.	3.6	15
144	No effect of dopamine depletion on the binding of the high-affinity D2/3 radiotracer [¹¹ C]FLB 457 in the human cortex. <i>Synapse</i> , 2010, 64, 879-885.	1.2	14

#	ARTICLE	IF	CITATIONS
145	Resting state synchrony in anxiety-related circuits of abstinent alcohol-dependent patients. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 433-440.	2.1	14
146	Kinetic Analysis of Drug-Target Interactions with PET for Characterization of Pharmacological Hysteresis. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2013, 33, 700-707.	4.3	13
147	Investigation of the Brain Biodistribution of the Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) Inhibitor [18F]GSK2647544 in Healthy Male Subjects. <i>Molecular Imaging and Biology</i> , 2017, 19, 153-161.	2.6	13
148	PET Radioligands for imaging of the PDE10A in human: current status. <i>Neuroscience Letters</i> , 2019, 691, 11-17.	2.1	13
149	Role of 18F-fluorodeoxyglucose Positron Emission Tomography in the Monitoring of Inflammatory Activity in Crohn's Disease. <i>Inflammatory Bowel Diseases</i> , 2016, 22, 2619-2629.	1.9	12
150	Imaging Synaptic Density: A Different Look at Neurologic Diseases. <i>Journal of Nuclear Medicine</i> , 2018, 59, 380-381.	5.0	12
151	First evaluation of PET-based human biodistribution and radiation dosimetry of 11C-BU99008, a tracer for imaging the imidazoline2 binding site. <i>EJNMMI Research</i> , 2018, 8, 71.	2.5	12
152	The role of phosphodiesterase 4 in excessive daytime sleepiness in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 163-169.	2.2	11
153	Kisspeptin modulates gamma-aminobutyric acid levels in the human brain. <i>Psychoneuroendocrinology</i> , 2021, 129, 105244.	2.7	11
154	Molecular and functional neuroimaging of human opioid receptor pharmacology. <i>Molecular Psychiatry</i> , 2011, 16, 785-785.	7.9	10
155	Patterns of Mitochondrial TSPO Binding in Cerebral Small Vessel Disease: An in vivo PET Study With Neuropathological Comparison. <i>Frontiers in Neurology</i> , 2020, 11, 541377.	2.4	9
156	Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [11C]PHNO PET. <i>Neuropsychopharmacology</i> , 2022, 47, 1405-1412.	5.4	9
157	Adenosine A2A receptor in schizophrenia: an in vivo brain PET imaging study. <i>Psychopharmacology</i> , 2022, 239, 3439-3445.	3.1	8
158	Kinetic analysis of neuroreceptor binding using PET. <i>International Congress Series</i> , 2004, 1265, 12-24.	0.2	7
159	Biodistribution and Radiation Dosimetry of the Serotonin 5-HT6 Ligand [11C]GSK215083 Determined from Human Whole-Body PET. <i>Molecular Imaging and Biology</i> , 2012, 14, 517-521.	2.6	7
160	Radiolabelling and in vivo evaluation of [11C]GSK215083 as potential PET radioligand for the 5-HT6 receptor in the porcine brain. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S598-S598.	4.3	7
161	Quantification of human brain PDE4 occupancy by GSK356278: A [11C](R)-rolipram PET study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2018, 38, 2033-2040.	4.3	6
162	In vivo occupancy of the 5-HT1A receptor by a novel pan 5-HT1(A/B/D) receptor antagonist, GSK588045, using positron emission tomography. <i>Neuropharmacology</i> , 2015, 92, 44-48.	4.1	4

#	ARTICLE	IF	CITATIONS
163	Specific and non-specific binding of a tracer for the translocator-specific protein in schizophrenia: an [¹¹ C]-PBR28 blocking study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3530-3539.	6.4	4
164	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [¹¹ C]-PHNO PET study. <i>Parkinsonism and Related Disorders</i> , 2021, 90, 52-56.	2.2	4
165	PET neuroimaging: The elephant unpacks his trunk. <i>NeuroImage</i> , 2014, 94, 408-410.	4.2	3
166	Acute acetate administration increases endogenous opioid levels in the human brain: A [¹¹ C]carfentanil molecular imaging study. <i>Journal of Psychopharmacology</i> , 2021, 35, 606-610.	4.0	3
167	Imaging the Dopamine D3 Receptor In Vivo. , 2014, , 265-287.		3
168	Imaging technologies in drug development: Anxiety and depression. <i>Drug Discovery Today: Technologies</i> , 2005, 2, 323-327.	4.0	2
169	State hospitals, academic medicine and the decline of health care in South Africa: A cry of support from those who have left for those who stay.. <i>South African Medical Journal</i> , 2010, 100, 74.	0.6	0
170	Pharmacokinetics and brain sigma 1 (σ ₁) receptor occupancy of MR309, a selective σ ₁ receptor antagonist. <i>British Journal of Clinical Pharmacology</i> , 2021, , .	2.4	0
171	The effect of ionic environments on the affinity of D2-dopamine receptor radioligands. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S616-S616.	4.3	0
172	5-HT _{1A} receptor density and defensive personality - interaction of neurochemistry, personality and depression explored with [¹¹ C]WAY 100635 PET. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2005, 25, S376-S376.	4.3	0
173	Psychiatry "Relevance with Respect to Drug Development, Examples. , 2012, , 535-557.		0